What’s the current market cap for Claritev Corporation stock?

Claritev Corporation (CTEV) has a market cap of $523m as of June 17, 2026.

What is the P/E ratio for Claritev Corporation stock?

The price to earnings (P/E) ratio for Claritev Corporation (CTEV) stock is 0 as of June 17, 2026.

Does Claritev Corporation stock pay dividends?

No, Claritev Corporation (CTEV) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Claritev Corporation dividend payment date?

Claritev Corporation (CTEV) stock does not pay dividends to its shareholders.

What is the beta indicator for Claritev Corporation?

Claritev Corporation (CTEV) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Claritev Corporation stock | $CTEV Share Price

About Claritev Corporation

Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.

Ticker

$CTEV

Sector

Health

Primary listing

NYSE

Employees

3,000

Headquarters

McLean, United States

Website

www.claritev.com

CTEV Metrics

BasicAdvanced

$523m

-

-$17.33

0.77

-

Bulls say / Bears say

In Q1 2026 Claritev delivered revenue of $244.7 million (up 5.8% YoY) and adjusted EBITDA of $146.9 million (up 3.4% YoY), reflecting continued top-line momentum and operational leverage (Business Wire (businesswire.com)).

The May 2026 launch of PHCS Novera provides TPAs with a flexible, regional-plus-national primary network solution, enhancing Claritev’s competitive positioning in network services amid escalating healthcare costs (Business Wire (businesswire.com)).

Management highlighted significant Q1 bookings wins in provider and government verticals, demonstrating successful diversification of Claritev’s client base beyond traditional payor markets and bolstering long-term growth prospects (Business Wire (businesswire.com)).

Claritev generated negative free cash flow of $92.5 million in Q1 2026, with net cash used in operating activities of $45.8 million eroding the $21.3 million cash balance and raising liquidity concerns (Business Wire (businesswire.com)).

Adjusted EBITDA margin contracted to 60.0% in Q1 2026 from 61.4% in Q1 2025, indicating pressure on Claritev’s operating efficiency amid rising costs (Business Wire (businesswire.com)).

Claritev received a confidential grand jury subpoena from the DOJ’s Antitrust Division in August 2024, and the ongoing investigation, though Claritev is not named as a target, poses potential regulatory and reputational risks (SEC 8-K Filing (sec.gov)).

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

CTEV News

AllArticlesVideos

CTEV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Claritev Corporation

Business Wire·3 weeks ago

The High-Yield Stocks the Smart Money Is Buying Right Now

Benzinga·3 weeks ago

Securities Fraud Investigation Into Claritev Corporation (CTEV) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Business Wire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.